SynopsisSomatuline is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome The global Somatuline market was valued at US$ 1401 million in 2023 and is anticipated to reach US$ 1506.5 milli.....
SynopsisOctreotide (trade name Sandostatin, among others) is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent inhibitor of growth hormone, glucagon, and insulin than the natural hormone. The global Sandostatin LAR Dru.....
SynopsisPasireotide is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. The global Pasireotide Drugs market was valued at US$ 104.5 million in 2023 and is .....
SynopsisSignifor is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. The global Signifor Drugs market was valued at US$ 104.5 million in 2023 and is antici.....
SynopsisLanreotide (INN) is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome The global Lanreotide Drugs market was valued at US$ 1401 million in 2023 and is anticipated to reach US$ .....
SynopsisSomatuline is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome The global Somatuline Drugs market was valued at US$ 1401 million in 2023 and is anticipated to reach US$ 1506.5.....
SynopsisPegvisomant(trade name Somavert) is a growth hormone receptor antagonist used in the treatment of acromegaly. The global Pegvisomant market was valued at US$ 268 million in 2023 and is anticipated to reach US$ 331.5 million by 2030, witnessing a CAGR of .....
SynopsisPegvisomant(trade name Somavert) is a growth hormone receptor antagonist used in the treatment of acromegaly. The global Somavert market was valued at US$ 268 million in 2023 and is anticipated to reach US$ 331.5 million by 2030, witnessing a CAGR of 3.1.....
SynopsisPegvisomant(trade name Somavert) is a growth hormone receptor antagonist used in the treatment of acromegaly. The global Pegvisomant Drugs market was valued at US$ 268 million in 2023 and is anticipated to reach US$ 331.5 million by 2030, witnessing a CA.....
SynopsisPegvisomant(trade name Somavert) is a growth hormone receptor antagonist used in the treatment of acromegaly. The global Somavert Drugs market was valued at US$ 268 million in 2023 and is anticipated to reach US$ 331.5 million by 2030, witnessing a CAGR .....
